Lexicon Announces Proposed Common Stock Offering Of $50M In Shares

Lexicon Pharmaceuticals, Inc.

today announced that it commenced an offering to sell, subject to market and other conditions, $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to $7,500,000 of additional shares of common stock. All of the shares in the offering are to be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. will be acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated will be acting as co-managers for the offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted. The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus forming a part of the effective shelf registration statement, copies of which may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204 or from Goldman, Sachs & Co., 200 West Street, New York, NY 10282, Attention: Prospectus Department, or by telephone at 866-471-2526 or by e-mail at prospectus-ny@ny.email.gs.com. The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and related preliminary prospectus supplement and other documents that the issuer has filed or will file with the Securities and Exchange Commission for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the Securities and Exchange Commission's website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.